國家衛生研究院 NHRI:Item 3990099045/9188

NHRI > National Institute of Infectious Diseases and Vaccinology > Pele Choi-Sing Chong > Periodical Articles > Item 3990099045/9188

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/9188

Title:	Recombinant lipoprotein-based vaccine candidates against C. difficile infections
Authors:	Huang, JH;Wu, CW;Lien, SP;Leng, CH;Hsiao, KN;Liu, SJ;Chen, HW;Siu, LK;Chong, P
Contributors:	Division of Vaccine Research and Development;Division of Infectious Diseases
Abstract:	Background: Opportunistically nosocomial infections in hospitalized patients are often related to Clostridium difficile infections (CDI) due to disruption of the intestinal micro-flora by antibiotic therapies during hospitalization. Clostridial exotoxins A and B (TcdA and TcdB) specifically bind to unknown glycoprotein(s) in the host intestine, disrupt the intestinal barrier leading to acute inflammation and diarrhea. The C-terminal receptor binding domain of TcdA (A-rRBD) has been shown to elicit antibody responses that neutralize TcdA toxicity in Vero cell cytotoxicity assays, but not effectively protect hamsters against a lethal dose challenge of C. difficile spores. To develop an effective recombinant subunit vaccine against CDI, A-rRBD was lipidated (rlipoA-RBD) as a rational design to contain an intrinsic adjuvant, a toll-like receptor 2 agonist and expressed in Escherichia coli. Results: The purified rlipoA-RBD was characterized immunologically and found to have the following properties: (a) mice, hamsters and rabbits vaccinated with 3 μg of rlipoA-RBD produced strong antibody responses that neutralized TcdA toxicity in Vero cell cytotoxicity assays; furthermore, the neutralization titer was comparable to those obtained from antisera immunized either with 10 μg of TcdA toxoid or 30 μg of A-rRBD; (b) rlipoA-RBD elicited immune responses and protected mice from TcdA challenge, but offered insignificant protection (10 to 20 %) against C. difficile spores challenge in hamster models; (c) only rlipoA-RBD formulated with B-rRBD consistently confers protection (90 to 100 %) in the hamster challenge model; and (d) rlipoA-RBD was found to be 10-fold more potent than A-rRBD as an adjuvant to enhancing immune responses against a poor antigen such as ovalbumin. Conclusion: These results indicate that rlipoA-RBD formulated with B-rRBD could be an excellent vaccine candidate for preclinical studies and future clinical trials.
Date:	2015-08-07
Relation:	Journal of Biomedical Science. 2015 Aug 7;22:Article number 65.
Link to:	http://dx.doi.org/10.1186/s12929-015-0171-x
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1021-7770&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000358981900001
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84938792696
Appears in Collections:	[Pele Choi-Sing Chong] Periodical Articles [Hsin-Wei Chen] Periodical Articles [Shih-Jen Liu] Periodical Articles [Chih-Hsiang Leng] Periodical Articles [Leung-Kei Siu] Periodical Articles

Files in This Item:

File	Description	Size	Format
SCP84938792696.pdf		2153Kb	Adobe PDF	548	View/Open

Loading...